About Genes2me
Genes2me is a company based in Gurugram (India) founded in 2016 by Ritu Gupta. Genes2me offers products and services including NGS Clinical Assays, Point-of-Care RT-PCR Testing, IVD RT-PCR Testing, Nucleic Acid Extraction, and Rapid Test Kits. Genes2me operates in a competitive market with competitors including Natera, ArcherDX, Variantyx, ImaginAb and Lantern Pharma, among others.
- Headquarter Gurugram, India
- Founders Ritu Gupta
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genes2me Private Limited
- Jurisdiction Delhi, Delhi, India
-
Annual Revenue
$6.56 M (USD)-73.67as on Mar 31, 2023
-
Net Profit
$343.82 K (USD)-88as on Mar 31, 2023
-
EBITDA
-$979.07 K (USD)-129.79as on Mar 31, 2023
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Genes2me
Genes2me offers a comprehensive portfolio of products and services, including NGS Clinical Assays, Point-of-Care RT-PCR Testing, IVD RT-PCR Testing, Nucleic Acid Extraction, and Rapid Test Kits.
Solutions for sequencing genetic disorders and personalized medicine.
Rapid molecular tests for on-site disease detection.
Kits for accurate virus and pathogen detection in labs.
Products for efficient DNA and RNA extraction processes.
Quick tests for detecting infections like COVID-19.
People of Genes2me
Unlock access to complete
Funding Insights of Genes2me
Detailed funding history for Genes2me
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genes2me
Investment portfolio details for Genes2me
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genes2me
Detailed financials for Genes2me
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genes2me Comparisons
Peer comparison for Genes2me
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genes2me
Genes2me operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, ArcherDX, Variantyx, ImaginAb and Lantern Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Genomics data analysis platform for healthcare diagnostics is offered.
|
|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Drug and companion diagnostics for multi-drug resistant cancers are developed.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
Detailed competitors of Genes2me
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genes2me
Complete news archive for Genes2me
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genes2me
Genes2me was founded in 2016.
Genes2me is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.
Annual revenue of Genes2me is $6.56M as on Mar 31, 2023.
Genes2me was founded in 2016 in Gurugram, India, and operates in the personalized healthcare sector. Genetics and molecular diagnostics are utilized to offer services such as non-invasive prenatal screening, genetic oncology, and screenings for disorders including beta-thalassemia and cystic fibrosis. Additional offerings include HPV testing, blood group typing, and general health and wellness assessments for mothers and children.
Genes2me's top competitors include Natera, ImaginAb and Lantern Pharma.
Genes2me offers NGS Clinical Assays, Point-of-Care RT-PCR Testing, IVD RT-PCR Testing, Nucleic Acid Extraction, and Rapid Test Kits.